Literature DB >> 12544982

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.

Peter Q Eichacker1, Charles Natanson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12544982     DOI： 10.1097/00003246-200301001-00013

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  11 in total

1.  Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.

Authors:  James M O'Brien; Scott K Aberegg; Naeem A Ali; Gregory B Diette; Stanley Lemeshow
Journal:  J Crit Care       Date:  2010-06-19       Impact factor: 3.425

2.  Increasing evidence that the risks of rhAPC may outweigh its benefits.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

3.  [Endogenous anticoagulant therapy for sepsis. Success and failure].

Authors:  C J Wiedermann
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743

4.  Science, medicine and industry: are we getting out of the black hole in sepsis research?

Authors:  Peter M Suter; Jukka Takala
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

5.  An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

Authors:  Michael A Fischer; Craig M Lilly; William W Churchill; Lindsey R Baden; Jerry Avorn
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  Recombinant human activated protein C for severe sepsis in neonates.

Authors:  Ranjit I Kylat; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 7.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

8.  [Patients in circulatory shock in emergency and intensive care units].

Authors:  A N Laggner
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

Review 9.  The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.

Authors:  P C Minneci; K J Deans; P Q Eichacker; C Natanson
Journal:  Clin Microbiol Infect       Date:  2009-04       Impact factor: 8.067

10.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.